Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

OTC Awards

- PMLiVE

The goldfish principle: making sense of persuasive communication

By Susan Walkley

- PMLiVE

Using knowledge graphs to discover powerful new insights

Looking at how multidimensional knowledge graphs work and their potential within the life sciences industry

- PMLiVE

Pfizer’s Litfulo approved by FDA as first treatment for adolescents with severe alopecia areata

Almost 20% of patients with the autoimmune disease are diagnosed before the age of 18

- PMLiVE

Sanofi and Sobi’s haemophilia A treatment shows effective bleed protection in children

Current factor VIII therapies usually require patients to receive treatment multiple times a week

- PMLiVE

International Respiratory Coalition urges policymakers to help lift disease burden

The societal and economic cost of respiratory disease in Europe is reportedly over €600bn

- PMLiVE

Swordfish Advertising appoints Sarah Rush as new CEO

Rush has been serving as the agency’s client services director since 2019

- PMLiVE

The patient voice

We believe that listening to people's lived experiences are vital components of our work.

Havas Life London

- PMLiVE

Strategies for engaging patients in the digital age

By Laura Meade

- PMLiVE

The MM+M Agency 100 report: Oxford PharmaGenesis is recognized as an industry leader for the third year running

We have scored a hat-trick, with media brand Medical Marketing and Media (MM+M) listing Oxford PharmaGenesis in its Agency 100 report for a third consecutive year.

Oxford PharmaGenesis

- PMLiVE

FDA grants accelerated approval to Sarepta’s Duchenne muscular dystrophy gene therapy

The disease occurs in up to one in every 5,000 newborn males worldwide

- PMLiVE

World Health Organization publishes research agenda for antimicrobial resistance

AMR has been declared by WHO as one of the top ten threats to global public health

- PMLiVE

Amgen’s supplemental Biologics License Application for Blincyto approved by FDA

The approval for the leukaemia drug was supported by additional data from two phase 3 studies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links